Swedish - American Life Science Summit Stockholm August 20, 2009

Magnus Nilsson, CEO

Agenda

• Company background• Market presence and growth• Product/therapy areas• Outlook 2009

2

Vitrolife – a global life science company

• A global life science company (Bio-Med Tech). Main sites in Gothenburg and Denver, Colorado

• Developing, manufacturing and selling nutrient solutions (media) and instruments for fertility treatments and lung transplantations.

• Growing and profitable business founded in 1994.

• Approx 160 employees.

• Sales in more than 85 countries. Local presence Nordic countries, US, Canada, Italy, Benelux, Austria, Germany, China, Japan, Australia, France

• Listed on the OMX Nordic Exchange’s Nordic Small Cap list since 2001. 3

Company Background

Vitrolife strives to be the leading supplier of media and other advanced disposables, used by hospitals and laboratories performing fertility treatment and other therapies where cells or tissues are used or are a part of the therapy.

Our Vision

4

Company Background

Vitrolife – Strategy

5

Company Background

A Process organisation to reflect the value chain

6

Order to Delivery

Company Background

Purchasing Production QC Sales Order Distribution

Product Life Cycle Management

Product idea valuation Product development Marketing

Supporting ProcessesQuality Assurance Finance/Information IT Human Resources Administration

Vitrolife – Reaching the global market

New offices in China and Japan 2009

7

Market presence and growth

Sales by region rolling 12 months

8

Market presence and growth

Sales and growth rate 2009

9

Market presence and growth

Sales and growth rate 2009 - Fertility

10~ 1.0 million cycles performed world wide per year

Market presence and growth

Regional share of global cycles

Growth rate for VitrolifeGrowth rate for Vitrolife

Share of sales of Vitrolife

Highlights of 2009• Sales first half year +23%

• Increased investment in R&D and marketing

• Fertility: Strong development in Asia, Europe and Middle East

• Transplantation: Positive progress for the clinical study in Canada for STEEN Solution™

• Successfull start up of the new offices in Asia

• Dividend 0.40 SEK/share paid out

• EBITDA 28,4% of sales

• Operating margin 14,4%

24 quarters of continuous operating profits

26 quarters in a row with better sales than previous year11

Market presence and growth

Key Financials: Investing in growth for the future

SEKm

12

0

20

40

60

80

100

120

140

160

180

200

2005 Q

1

2005 Q

2

2005 Q

3

2005 Q

4

2006 Q

1

2006 Q

2

2006 Q

3

2006 Q

4

2007 Q

1

2007 Q

2

2007 Q

3

2007 Q

4

2008 Q

1

2008 Q

2

2008 Q

3

2008 Q

4

2009 Q

1

2009 Q

2

Gross Income Operating Income before R&D EBITDA Operating Income Income after financial items

Investing in growth

Investing in growth14% of Sales invested in 14% of Sales invested in

R&D activitiesR&D activities

Market presence and growth

Product areas - a genius combination

Customers/markets:

• Private and public clinics/ specialized laboratories

• ~ 3000 clinics

• Partly subsidized

• ~ 1 million clin. IVF treatm.

Customers/markets:

• Public specialized laboratories /research institutions and private companies

• ~ 400 institutions / 150 companies

• Subsidized & private

• Research, in clinics 2-5 years

Customers/markets:

• Public clinics

• ~ 200 Lung transpl clinics / ~ 2000 all transplantations

• Subsidized

• ~ 3000 Lungs/ ~ 50000 all transplantations

FERTILITY TRANSPLANTATIONSTEM CELL CULTIVATION

13

Product /Therapy areas

Fertility – Competitive advantage

New unique needle for the collection of human oocytes, Swemed Sense™, recently launched and approved for

sales in Europe– Potential market estimated to EUR 50 million

• A complete range of advanced clinical products

• Regulatory approval– CE mark– FDA 510(k)

• State of the art production facilities

• Industry leading QC

• Global market reach

• External collaboration with the leading scientist

FERTILITY

14

Product /Therapy areas

ICSI Medium

Pharmaceutical-grade media

IVF™-50

First sequential

media G1™/ G2™ v. 2

Beyond HSA –Recombinant

media r-S1™/ r-S2™

Closer to NatureGIII Series™ v.3

EmbryoGlue®Implantation

promoting medium

1994 1995 1998 2001 2002

2003 2004 2005 2006 2007 2008

GIII Series ™ CE marked

Acquisition of SWEMED lab

Ultrarapid vitrification

Unique aspiration needle –

SWEMED ™ Sense

New technique -follicle aspiration

needle with ultrasound probe

1983

History of Innovations

15

FERTILITY

Breakthrough InnovationsBreakthrough Innovations

Product /Therapy areas

Product portfolio development

Strategy: Portfolio expansion through R&D and acquisitions to optimize market synergies:

FERTILITY

16

Target: Increase product offering value per cycle with 50%

Product /Therapy areas

STEM CELL CULTIVATIONStem Cell cultivation

• Products for human embryo stem cells and cryo preservation of stem cells

• State of the art production facilities

• Industry leading QC

• Cooperation with leading scientist

In VitroHes researchers can successfully grow human stem cells and maintain pluri potency

17

Product /Therapy areas

STEM CELL CULTIVATIONGiant market expectations in cell therapy

18

TechnologyMarket Size

2007Market Size

2012Market Size

2017Time increase 2007 to 2017

Stem cell transplant $2.4 billion $5.3 billion $11.3 billion 4.7x

Supporting technologies: cell lines, cell culture, delivery devices $2.6 billion $5.9 billion $10.2 billion 4x

Cell-based gene therapy $1.7 billion $3.2 billion $6.0 billion 3.5x

Cord blood collection therapy $0.7 billion $1.1 billion $2.5 billion 3.6x

Product /Therapy areas

Source: Jain Pharmatech

STEM CELL CULTIVATIONCell Therapy – Situation analysis

• Clinical applications for MSC, HSC, CBSC, FNSC

• >3 years before therapies based on hESC reach clinic due to:

– Difficulties to control differentiation– Scaling up production– Ethically controversial– Regulatory authorities

19

Product /Therapy areas

STEM CELL CULTIVATIONStem cell culture media – Regulatory

Harmonisation of regulatory requirements and a long term view is a need for a safe treatment

• US– Regulated by FDA/ CBER– Classified as Class 1 Medical

Device, exempted from 510(k)

• EU– Classified as non Medical Device– To be produced according to GMP

20

Product /Therapy areas

STEM CELL CULTIVATIONStem Cell Cultivation – Focus areas

• Increase focus on development of new ”clinical grade” stem cell media together with our partners.

• Fulfill the clinical requirements as set out in other areas

21

Product /Therapy areas

Transplantation – the new wayTRANSPLANTATION

22

The new method radically increases the availability of organs for transplantation

• Pioneering lung perfusion system (ex vivo and at 37ºC)

– Clinical trial in North America of Steen Solution™

– Innovative equipment for organ evaluation ex vivo

• Development of perfusion systems for other organs

– Preclinical trials with other organs e.g. liver, heart

Product /Therapy areas

STEEN Solution™ - Focus Area

• Finish clinical studies in North America and apply for marketing authorization for Steen Solution™ in the U.S. Clinical results so far very promising.

• 25 lungtransplantations performed in clinic so far

• Continue launch of STEEN Solution™ in Europe by training and education in the STEEN Solution™ method to get market acceptance

• Developing of and clinical trials with additional products needed for a lung-assessment with Steen Solution ™.

TRANSPLANTATION

23

Product /Therapy areas

Vitrolife – STEEN SolutionTM

• >70% of donated organs are not used

• Too few organs to transplant

• Short of time, a maximum of 8-12 hours outside the body

• Patients die while waiting for organs

• Functional testing

• Large number of potential donors

(including donation after cardiac death)

• Maximum time >24 hours outside the body

• More patients can be provided with new

lungs

Problem

• More organs can be used

• More organs available for

transplantation

• More organs can be used in time (lower

cost)

• Fewer deaths caused by lack of organs

STEEN Solution™ Advantage

24

TRANSPLANTATION

Product /Therapy areas

Vitrolife – STEEN SolutionTM

Before STEEN Sol.

Costs for products per evaluation (SEK) ca 10.000 > 30.000

Potential number of transplantations ca 3.000 > 20.000

Market potential*, lungs only (SEK million) ca 35 > 600

* Including research market

Approved in Europe 2006, and in Australia 2008.The method is also being developed for other organs, e.g. liver.

25

TRANSPLANTATION

Product /Therapy areas

Outlook 2009• Continued execution of main strategy:

– Establish direct sales on all major markets covering 80% of all treatments

– Exploit market synergies with broader product portfolio through development and/or acquisitions

– Increase gross margin through continuous improvement of operations

• One major new product launch in Product Area Fertility

• Support launch of STEEN Solution™ in Europe and prepare for market introduction in USA and Canada

• Strong R&D focus with gradually increasing efforts in Transplantation and Stem Cell Cultivation

• Maintain profitable growth and operational strong cash flow 26

Outlook 2009

…investing in growth

With sustainable profit & cash flow…

…reaching the global market

…for the future